

ARTICLES OF ASSOCIATION

of

BAVARIAN NORDIC A/S

CVR no. 16271187

NAME, OBJECTS OF THE COMPANY AND CORPORATE LANGUAGE

Article 1

The name of the company is Bavarian Nordic A/S ("the Company").

Article 2

The objects for which the Company has been established is to carry on research, trade, manufacture and any other related activities, primarily within the pharmaceutical industry.

Article 3

Subsection 1

The Company has English as corporate language and company announcements are published in English.

Subsection 2

General meetings are held in English with or without translation into Danish. Documents prepared for use by general meetings, including the notice convening the general meeting and the agenda with the complete proposals as well as any additional material, are prepared in English.

THE COMPANY'S SHARE CAPITAL

Article 4

The Company's share capital amounts to DKK 792,367,280 in words sevenhundredninetwomillionthreehundredsixtyseventhousandtwohundredandeighty 00/100 Danish kroner, divided into shares in the denomination of DKK 1 and multiples thereof. The share capital has been paid up in full.

AUTHORISATION TO INCREASE THE SHARE CAPITAL

Article 5a

Subsection 1

For the period ending on 30 June 2026, the Board of Directors is authorized to increase the Company's share capital in one or more issues with a total of up to nominally DKK 78,854,850 (7,885,485 shares of DKK 10 each) by the subscription of new shares. The existing shareholders shall have pre-emption rights to subscribe for the amount by which the share capital is increased, proportional to their shareholdings. The share capital shall be increased by cash payment at a subscription price which may be lower than the value of the shares.

The terms and conditions of the subscription for shares shall be determined by the Board of Directors.

The new shares shall be negotiable instruments, shall be registered in the names of the holders and shall be entered in the Company's register of shareholders. No restrictions

shall apply to the transferability of the new shares, and no shareholder shall be obliged to have his shares redeemed – in whole or in part. The shares shall carry the right to dividend as from the date fixed by the Board of Directors, but not later than the first financial year following the capital increase.

Subsection 2

For the period ending on 30 June 2026, the Board of Directors is authorized to increase the Company's share capital in one or more issues with a total of up to nominally DKK 78,854,850 (7,885,485 shares of DKK 10 each) by the subscription of new shares. The existing shareholders shall not have pre-emption rights to subscribe for the amount by which the share capital is increased.

The share capital may be increased by cash payment or in other ways, such as by conversion of debts or in payment of a contribution in kind. The share capital shall in any event be increased at a subscription price, which is not lower than market value.

The terms and conditions of the subscription for shares shall be determined by the Board of Directors.

The new shares shall be negotiable instruments, shall be registered in the names of the holders and shall be entered in the Company's register of shareholders. No restrictions shall apply to the transferability of the new shares, and no shareholder shall be obliged to have his shares redeemed – in whole or in part. The shares shall carry the right to dividend as from the date fixed by the Board of Directors, but not later than the first financial year following the capital increase.

Subsection 3

When exercising the authorizations given in Articles 5a(1), 5a(2), and 5a(4) the Board of Directors is in total authorized to increase the share capital of the Company with a total of up to nominally DKK 78,854,850 (7,885,485 shares of DKK 10 each).

Subsection 4

For the period ending on 30 June 2026, the Board of Directors is authorized to obtain loans in the Company by issue of convertible notes that give the right to subscribe for new shares in the Company by a maximum nominal value of up to DKK 78,854,850. The Company's existing shareholders shall not have pre-emption rights to grant loans. The loans shall be paid in cash. The terms and conditions for the loans and the convertible notes shall be determined by the Board of Directors.

As a consequence of the conversion of the convertible notes, the Board of Directors is authorized for the period ending 30 June 2026 to increase the Company's share capital by a nominal value of up to DKK 78,854,850 (7,885,485 shares of DKK 10 each) in one or more portions by resolution of the Board of Directors by conversion of the convertible notes and on such other terms as the Board of Directors may determine. The Company's existing shareholders shall not have pre-emption right to subscribe for shares issued by conversion of the convertible notes.

The new shares issued based on convertible notes shall have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders and shall be entered in the Company's register of shareholders. No restrictions shall apply to the transferability of the new shares, and no shareholder shall be obliged to have his shares redeemed – in whole or in part. The new shares shall carry the right to dividend from the time of conversion of the issued convertible notes, i.e. from the time of subscription.

Article 5b

During the period ending 31 December 2026, the Company may issue warrants, in one or more portions by resolution of the Board of Directors. The warrants may be issued to employees of the Company or its subsidiaries for the subscription of a nominal value of up to DKK 8,600,430 (860,043 shares of DKK 10 each), however, the number of shares may be higher or lower due to subsequent adjustments of the warrants in accordance with the adjustment clauses determined by the Board of Directors when the warrants are issued. The warrants can be exercised by cash contribution at a subscription price and on such other terms as the Board of Directors may determine. Warrants may not be granted to members of the management or to members of the Company's Board of Directors (except for employee representatives (if such may have been elected) who receive warrants in their capacity as employees of the Company or of the Company's subsidiaries).

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders are deviated from.

As a consequence of the exercise of awarded warrants, the Board of Directors is authorized during the period until 1 April 2030 to increase the share capital by a nominal value of up to DKK 8,600,430 (860,043 shares of DKK 10 each) in one or more portions by resolution of the Board of Directors by cash contribution at a subscription price and on such other terms as the Board of Directors may determine without pre-emption right for the existing shareholders, however, the number of shares by which the share capital may be increased may be higher or lower if the number of warrants is increased in accordance with the adjustment clauses determined by the Board of Directors when the warrants are issued.

The new shares issued based on warrants shall have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders and shall be entered in the Company's register of shareholders. No restrictions shall apply to the transferability of the new shares and no shareholder shall be obliged to have his shares redeemed – in whole or in part. The new shares shall carry the right to dividend from the time of subscription.

Subject to the rules in force at any time, the Board of Directors may reuse or reissue lapsed and unexercised warrants if any, provided that the reuse or reissue occurs under the terms and within the time limitations set out in this authorization. Reuse is to be construed as the Board of Directors' entitlement to let another party enter into an existing agreement on warrants. Reissue is to be construed as the Board of Directors' option to reissue new warrants, under the same authorization, if previously issued warrants have lapsed.

Article 5c
(Exercised)

Article 5d

In accordance with authorisations from the general meeting, the Board of Directors has issued warrants as set out in appendix 1 to the Articles of Association. As required by the Danish Companies Act and as set out in appendix 1, the Board of Directors has determined the adjustment clauses that apply to the warrants in the event of changes that affect the Company's share capital etc. The purpose of the adjustment clauses is to ensure that the potential gain on the warrants remain unchanged in the event of such changes. Consequently, the number of shares by which the share capital may be increased will automatically be higher or lower than the maximum number set out in the original authorizations granted by the general meeting if the warrants are adjusted in accordance with the adjustment clauses.

SHARES

Article 6

All shares shall be registered in the names of the holders and shall be entered in the Company's register of shareholders. The shares shall be negotiable instruments and there shall be no restrictions as to their transferability.

Article 7

No share shall confer any special rights upon the holder, and no shareholder shall be obliged to have his shares redeemed, whether in whole or in part, by the Company or by any other party.

Article 8

As resolved by the Board of Directors, the Company's register of shareholders may be kept either by the Company, or by a secretary outside the Company to be designated by the Board of Directors. The Company's register of shareholders is kept by Computershare A/S, CVR no. 27088899.

Article 9

Share certificates may be declared null and void without a prior court order in accordance with the statutory rules applying from time to time to the annulment of negotiable instruments.

GENERAL MEETINGS

Article 10

The general meeting has the supreme authority in all the Company's affairs, subject to statute and to these Articles of Association.

General Meetings shall be held in the municipality in which the Company's registered office is situated, or in the Capital Region of Denmark (in Danish Region Hovedstaden).

General Meetings shall be convened by the Board of Directors giving not less than three weeks' nor more than five weeks' notice.

General meetings shall be convened by publication on the Company's webpage. The Board of Directors may resolve that notice to convene the general meeting shall be published in a leading newspaper. Furthermore, a written notice convening the general meeting shall be sent to all registered shareholders who have so requested.

The convening notice shall contain the agenda of the relevant General Meeting. If any proposals are to be considered at the General Meeting, the adoption of which is subject to a special majority, then this fact shall be emphasized in the convening notice and the essentials of the relevant proposal shall be reproduced in it.

Article 11

Each share amount of DKK 10 shall give one vote at General Meetings. Any shareholder may cast different votes in respect of his shares. Any shareholder shall be entitled to attend the General Meeting and exercise his voting rights, provided that he has requested an admission card from the Company's offices no later than three days prior to the pertinent meeting. His capacity as a shareholder shall be documented by his title having been registered in the Company's register of shareholders no later than one week prior to the general meeting or by the Company having received his application for entry of the title in the register of shareholders before this date.

The shareholder may attend in person or be represented by proxy, and is entitled to attend together with an advisor.

The proxy holder must provide a dated and written proxy issued to a person who does not need to be a shareholder in the Company. Unless containing a provision to the contrary, proxies shall be deemed to be in force until revoked in writing by notification to the Company. However, proxies issued to the Company's Board of Directors may not be issued for a period of more than 12 months and may only be issued in respect of a specific general meeting for which the agenda is known in advance.

Article 12

The ordinary general meeting shall be held in time to allow for the audited and approved annual report to be received in the Danish Business Authority no later than 4 months after the end of the financial year.

The agenda of the Annual General Meeting shall contain the following business:

1. The Board of Directors' report on the Company's activities in the past year.
2. The presentation of the annual report for adoption.
3. A proposal from the Board of Directors regarding the application of profit or covering of loss pursuant to the annual report as adopted.
4. Presentation of and indicative vote on the Remuneration Report.
5. A resolution for ratification of the acts of the Board of Directors and the Board of Management.
6. Election of members to the Board of Directors.
7. Election of auditors.
8. Any proposals from the Board of Directors or shareholders, including proposals authorising the Company to acquire shares of Company stock.

Requests from shareholders for proposals for consideration at the Annual General Meeting must be lodged with the Company no later than six weeks before the general meeting. Are requests made later than six weeks before the general meeting, the Board of Directors decides whether the proposals can be admitted to the agenda.

Article 13

Extraordinary General Meetings shall be held if requested by the General Meeting, the Board of Directors or an auditor, or by written request to the Board of Directors from shareholders holding in the aggregate not less than 1/20 of the share capital. The request from the shareholders must contain a specification of the business desired to be considered at the General Meeting. The General Meeting shall be convened no later than 14 days after the appropriate request having reached the Board of Directors.

Article 14

A chairman appointed by the Board of Directors shall preside over the General Meeting.

The Chairman shall officiate at the General Meeting and shall settle all matters relating to the transaction of business.

Minutes of the proceedings at a General Meeting shall be entered in a Minute Book, such minutes to be signed by the Chairman and all members of the Board of Directors present at the General Meeting.

No later than 14 days after a General Meeting, the Minute Book and the results of the voting shall be available for the shareholders on the Company's webpage.

VOTING RIGHTS

Article 15
Cancelled

Article 16

All resolutions put to the vote of shareholders at General Meetings shall be subject to adoption by a simple majority of votes, unless the Danish Companies Act or these Articles of Association prescribe special rules regarding representation and majority.

Unless a greater majority or unanimity is required pursuant to legislation, the adoption of resolutions regarding amendment of these Articles of Association, the dissolution of the Company or its merger or amalgamation with another company or business is subject to such resolution being adopted by not less than 2/3 of all the votes cast as well as of the votes represented at the relevant General Meeting.

BOARD OF DIRECTORS AND BOARD OF MANAGEMENT

Article 17

The Company shall be managed by a Board of Directors of not less than four nor more than seven members to be elected for one year at a time by the shareholders at the General Meeting. Retiring Directors shall be eligible for re-election. In addition to the Directors elected by the General Meeting, the Board of Directors may be comprised of such members that are to be elected pursuant to the statutory rules on employee representation.

The shareholders at the General Meeting shall determine the remuneration of the Board of Directors.

Article 18

Minutes shall be taken of all proceedings at Board Meetings. Such minutes shall be signed by all attending directors.

The Board of Directors shall elect its own chairman and deputy chairman.

The Board of Directors may grant powers of procuration to individuals to sign singly or collectively.

In addition, the Board of Directors shall lay down more specific Rules of Procedure regarding the discharge of its duties.

The Board of Directors shall appoint a Board of Management.

BINDING SIGNATURES

Article 19

The Company shall be bound in legal transactions by the joint signatures of the Chair of the Board of Directors and that of either a member of the Board of Management or any two members of the Board of Directors, or by the joint signatures of any two members of the Board of Directors and any member of the Board of Management or by joint signatures of any two members of the Board of Management.

AUDITORS

Article 20

The Company's annual report shall be audited by one or two Danish state-authorized public accountants elected by the shareholders at the General Meeting.

Auditors shall be elected for a term of one year at a time. Retiring auditors shall be eligible for re-election.

ANNUAL REPORT

Article 21

The Company's financial year shall coincide with the calendar year.

The Annual Report and consolidated financial statements shall be prepared pursuant to the applicable legislation regarding the presentation of Annual Reports and the international standards in accordance with the IFRS Regulation.

Article 22

The Company's annual reports and interim financial reports are prepared in English. The Board of Directors may resolve that the annual report shall also be prepared in Danish.

GENERAL MEETINGS BY ELECTRONIC MEANS

Article 23

The Company's general meetings can be held by electronic means with no physical attendance possible. Participation in such general meetings shall take place via the Internet, on the Company's website and/or by videoconference.

---ooOoo---

As amended by the Board of Directors following the grant of warrants on 18 December 2025.

Appendix 1:

Cancelled (expired warrants).	Section 1
Cancelled (expired warrants).	Section 2
Cancelled (expired warrants).	Section 3
Cancelled (expired warrants).	Section 4
Cancelled (expired warrants).	Section 5
Cancelled (expired warrants).	Section 6
Cancelled (exercised and lapsed warrants).	Section 7
Cancelled (exercised and lapsed).	Section 8
Cancelled (exercise and lapsed warrants).	Section 9
Cancelled (exercised and lapsed warrants).	Section 10
Cancelled (exercised warrants).	Section 11
Cancelled (exercised and lapsed warrants).	Section 12
Cancelled (exercised and lapsed warrants).	Section 13
Cancelled (exercised and lapsed warrants).	Section 14
Cancelled (exercised and lapsed warrants).	Section 15

Section 16

Cancelled (exercised and lapsed warrants).

Section 17

Cancelled (exercised and lapsed warrants).

Section 18

Cancelled (exercised warrants).

Section 19

Cancelled (exercised and lapsed warrants).

Section 20

In accordance with authorisations in Article 5b of the Articles of Association and Section 19 of this Appendix 1, on 12 November 2021 the Board of Directors has issued and reissued 716,256 warrants, providing the right to subscribe to a maximum of 716,256 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 7,162,560), at a rate of DKK 353.06 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. 78,689 of the warrants have been reissued under Section 19 of this Appendix 1.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2024; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2025; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2025; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2025; (5) fifth time being after the publication of the Company's annual report for 2025; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2026; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2026; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2026. Warrants that are not exercised electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The

Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted, whether they have vested or not, and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be

adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 7,162,560 by cash payment at a price of DKK 353.06 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

The Board of Directors may during the period ending 31 December 2022 in one or more portions reuse or reissue any lapsed and unexercised warrants issued in accordance with Article 5b. Reuse is to be construed as the Board of Directors' entitlement to let another party enter into an existing agreement on warrants. Reissue

is to be construed as the Board of Directors' option to reissue new warrants, under the same authorisation, if previously issued warrants have lapsed.

The warrants may be reused or reissued to the management and employees of the Company or its subsidiaries. Warrants may be reissued for the subscription of shares by cash contribution at a subscription price and on such other terms as the Board of Directors may determine in accordance with the original authorisation. Any issuance of warrants to the management shall be made in accordance with the Company's remuneration policy.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

If and to the extent that warrants are reissued, the Board of Directors is authorised during the period until 1 April 2025 to resolve on the related capital increase by a nominal value of up to DKK 7,162,560 in one or more portions by cash contribution at a subscription price and on such other terms as the Board of Directors may determine without pre-emption right for the existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 21

In accordance with authorisations in Article 5b of the Articles of Association, on 1 April 2022 the Board of Directors has issued 63,157 warrants, providing the right to subscribe for up to 63,157 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 631,570), at a rate of DKK 190.11 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's quarterly report (Q2) for 6 months of 2025; (2) second time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2025; (3) third time being after the publication of the Company's annual report for 2025; (4) fourth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2026; (5) fifth time being after the publication of the Company's

quarterly report (Q2) for the first 6 months of 2026; (6) sixth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2026; (7) seventh time being after the publication of the Company's annual report for 2026; and/or (8) eighth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2027. Warrants that are not exercised electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to a third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted, whether they have vested or not, and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 631,570 by cash payment at a price of DKK 190.11 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq

Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

The Board of Directors may during the period ending 31 December 2022 in one or more portions reuse or reissue any lapsed and unexercised warrants issued in accordance with Article 5b. Reuse is to be construed as the Board of Directors' entitlement to let another party enter into an existing agreement on warrants. Reissue is to be construed as the Board of Directors' option to reissue new warrants, under the same authorisation, if previously issued warrants have lapsed.

The warrants may be reused or reissued to the management and employees of the Company or its subsidiaries. Warrants may be reissued for the subscription of shares by cash contribution at a subscription price and on such other terms as the Board of Directors may determine in accordance with the original authorisation. Any issuance of warrants to the management shall be made in accordance with the Company's remuneration policy.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

If and to the extent that warrants are reissued, the Board of Directors is authorised during the period until 1 April 2026 to resolve on the related capital increase by a nominal value of up to DKK 631,570 in one or more portions by cash contribution at a subscription price and on such other terms as the Board of Directors may determine without pre-emption right for the existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 22

In accordance with authorisations in Article 5b and Section 20 of this Appendix 1, on 8 December 2022 the Board of Directors has issued and reissued 683,264 warrants, providing the right to subscribe up to 683,264 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 6,832,640) at a rate of DKK 270.91 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. 56,957 of the warrants have been reissued under Section 20 of this Appendix 1.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2025; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2026; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2026; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2026; (5) fifth time being after the publication of the Company's annual report for 2026; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2027; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2027; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2027. Warrants that are not exercised electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an

existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 6,832,640 by cash payment at a price of DKK 270.91 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

The warrants granted contain a limitation, in that the total value of the shares that can be subscribed for by exercising the warrants, minus the subscription price that must be

paid when the shares are subscribed (the "net value"), at the time the warrants are exercised, must not exceed an amount equivalent to DKK 20 million. If the net value exceeds DKK 20 million, the number of warrants that can be exercised must be reduced so that the net value of the warrants does not exceed DKK 20 million.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 23

In accordance with authorisations in Article 5b and 5c of the Articles of Association, on 8 December 2022 the Board of Directors has issued 248,787 warrants to members of the Executive Management, providing for – if certain conditions are met – the right to subscribe for up to 248,787 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 2,487,870) at a rate of DKK 224.70 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. The issue of warrants has taken place in accordance with the company's remuneration policy.

In connection with the approval of the annual report for 2022, 2023 and 2024, or such other time as decided by the Board of Directors, the Board of Directors will determine the key performance indicators ("KPIs") that shall be fulfilled in order for the warrants granted to vest. The KPIs may include financial, non-financial, operational, strategic and/or sustainability targets. The Board of Directors will also determine the threshold and the level of performance to be obtained to achieve full or partly vesting of the granted warrants. The warrants will vest (wholly or partly) according to the following schedule, provided the KPI's have been fulfilled in full or in part as determined by the Board of Directors: Up to 1/3 of the granted Warrants will vest on 1 January 2024, up to 1/3 will vest on 1 January 2025 and up to 1/3 will vest on 1 January 2026. However, the Board of Directors may decide that overperformance on one or more KPIs in one vesting period may effect the number of Warrants that vest in the same or another vesting period in which not all warrants have vested. Overperformance on KPIs cannot result in vesting of more than 100% of the granted Warrants. Only vested warrants can be exercised.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2025; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2026; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2026; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2026; (5) fifth time being after the publication of the Company's annual report for 2026; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2027; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2027; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2027. Vested warrants that are not exercised in the first subscription period may be exercised in subsequent subscription periods, always provided that any vested warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from

exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse). The level of vesting of the warrants will be determined by the Board of Directors e.g. based on the level of fulfilment of the KPIs during the period from grant. Warrants that have not been vested, will lapse; or

That warrant holders will retain the warrants that have been granted on unchanged terms, including the terms for vesting.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of

shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 2,487,870 by cash payment at a price of DKK 224.70 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

Warrants granted include a cap in order that the total value of the shares that can be subscribed by exercise of the warrants less the price paid to subscribe for the shares (the "net value") does not at the time of exercise exceed an amount equivalent to DKK 50 million for the CEO and DKK 30 million for the CFO. The cap for warrants granted to non-registered Executive Management members is DKK 30 million.

If the net value exceeds the cap, the number of vested warrants that can be exercised shall be reduced in order that the net value of such warrants is within the cap.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq

Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 24

In accordance with authorisations in Article 5b, 5c and Section 20 of this Appendix 1, on 13 December 2023 the Board of Directors has issued and reissued 1,105,169 warrants, providing the right to subscribe up to 1,105,169 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 11,051,690) at a rate of DKK 191.58 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. 20,759 of the warrants have been reissued under Section 20 of this Appendix 1.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2026; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2027; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2027; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2027; (5) fifth time being after the publication of the Company's annual report for 2027; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2028; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2028; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2028. Warrants that are not exercised

electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any

loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 11,051,690 by cash payment at a price of DKK 191.58 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

The warrants granted contain a limitation, in that the total value of the shares that can be subscribed for by exercising the warrants, minus the subscription price that must be paid when the shares are subscribed (the "net value"), at the time the warrants are exercised, must not exceed an amount equivalent to DKK 20 million. If the net value exceeds DKK 20 million, the number of warrants that can be exercised must be reduced so that the net value of the warrants does not exceed DKK 20 million.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq

Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 25

In accordance with authorisations in Article 5b and 5c of the Articles of Association, on 13 December 2023 the Board of Directors has issued 161,412 warrants to members of the Executive Management, providing for – if certain conditions are met – the right to subscribe for up to 161,412 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 1,614,120) at a rate of DKK 172.40 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. The issue of warrants has taken place in accordance with the company's remuneration policy.

In connection with the approval of the annual report for 2023, 2024 and 2025, or such other time as decided by the Board of Directors, the Board of Directors will determine the key performance indicators ("KPIs") that shall be fulfilled in order for the warrants granted to vest. The KPIs may include financial, non-financial, operational, strategic and/or sustainability targets. The Board of Directors will also determine the threshold and the level of performance to be obtained to achieve full or partly vesting of the granted warrants. The warrants will vest (wholly or partly) according to the following schedule, provided the KPI's have been fulfilled in full or in part as determined by the Board of Directors: Up to 1/3 of the granted Warrants will vest on 1 January 2025, up to 1/3 will vest on 1 January 2026 and up to 1/3 will vest on 1 January 2027. However, the Board of Directors may decide that overperformance on one or more KPIs in one

vesting period may affect the number of Warrants that vest in the same or another vesting period in which not all warrants have vested. Overperformance on KPIs cannot result in vesting of more than 100% of the granted Warrants. Only vested warrants can be exercised.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2026; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2027; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2027; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2027; (5) fifth time being after the publication of the Company's annual report for 2027; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2028; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2028; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2028. Vested warrants that are not exercised in the first subscription period may be exercised in subsequent subscription periods, always provided that any vested warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse). The level of vesting of

the warrants will be determined by the Board of Directors e.g. based on the level of fulfilment of the KPIs during the period from grant. Warrants that have not been vested, will lapse; or

That warrant holders will retain the warrants that have been granted on unchanged terms, including the terms for vesting.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 1,614,120 by cash payment at a price of DKK 172.40 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

Warrants granted include a cap in order that the total value of the shares that can be subscribed by exercise of the warrants less the price paid to subscribe for the shares (the "net value") does not at the time of exercise exceed an amount equivalent to DKK 50 million for the CEO and DKK 30 million for the CFO. The cap for warrants granted to non-registered Executive Management members is DKK 30 million.

If the net value exceeds the cap, the number of vested warrants that can be exercised shall be reduced in order that the net value of such warrants is within the cap.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be affected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 26

In accordance with authorisations in Article 5b and Section 24 of this Appendix 1, on 13 December 2024 the Board of Directors has issued and reissued 1,053,509 warrants, providing the right to subscribe up to 1,053,509 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 10,535,090) at a rate of DKK 223.33 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. 104,802 of the warrants have been reissued under Section 24 of this Appendix 1.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2027; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2028; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2028; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2028; (5) fifth time being after the publication of the Company's annual report for 2028; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2029; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2029; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2029. Warrants that are not exercised electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an

existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 10,535,090 by cash payment at a price of DKK 223.33 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

The warrants granted contain a limitation, in that the total value of the shares that can be subscribed for by exercising the warrants, minus the subscription price that must be

paid when the shares are subscribed (the "net value"), at the time the warrants are exercised, must not exceed an amount equivalent to DKK 20 million. If the net value exceeds DKK 20 million, the number of warrants that can be exercised must be reduced so that the net value of the warrants does not exceed DKK 20 million.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 27

In accordance with authorisations in Article 5b of the Articles of Association, on 13 December 2024 the Board of Directors has issued 118,274 warrants to members of the Executive Management, providing for – if certain conditions are met – the right to subscribe for up to 118,274 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 1,182,740) at a rate of DKK 198.90 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. The issue of warrants has taken place in accordance with the company's remuneration policy.

In connection with the approval of the annual report for 2024, 2025 and 2026, or such other time as decided by the Board of Directors, the Board of Directors will determine the key performance indicators ("KPIs") that shall be fulfilled in order for the warrants granted to vest. The KPIs may include financial, non-financial, operational, strategic and/or sustainability targets. The Board of Directors will also determine the threshold and the level of performance to be obtained to achieve full or partly vesting of the granted warrants. The warrants will vest (wholly or partly) according to the following schedule, provided the KPI's have been fulfilled in full or in part as determined by the Board of Directors: Up to 1/3 of the granted Warrants will vest on 1 January 2026, up to 1/3 will vest on 1 January 2027 and up to 1/3 will vest on 1 January 2028. However, the Board of Directors may decide that overperformance on one or more KPIs in one vesting period may affect the number of Warrants that vest in the same or another vesting period in which not all warrants have vested. Overperformance on KPIs cannot result in vesting of more than 100% of the granted Warrants. Only vested warrants can be exercised.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2027; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2028; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2028; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2028; (5) fifth time being after the publication of the Company's annual report for 2028; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2029; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2029; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2029. Vested warrants that are not exercised in the first subscription period may be exercised in subsequent subscription periods, always provided that any vested warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from

exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse). The level of vesting of the warrants will be determined by the Board of Directors e.g. based on the level of fulfilment of the KPIs during the period from grant. Warrants that have not been vested, will lapse; or

That warrant holders will retain the warrants that have been granted on unchanged terms, including the terms for vesting.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of

shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 1,182,740 by cash payment at a price of DKK 198.90 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

Warrants granted include a cap in order that the total value of the shares that can be subscribed by exercise of the warrants less the price paid to subscribe for the shares (the "net value") does not at the time of exercise exceed an amount equivalent to DKK 50 million for the CEO and DKK 30 million for the CFO. The cap for warrants granted to non-registered Executive Management members is DKK 30 million.

If the net value exceeds the cap, the number of vested warrants that can be exercised shall be reduced in order that the net value of such warrants is within the cap.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be affected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq

Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.

Section 28

In accordance with authorisations in Article 5b and Section 26 of this Appendix 1, on 18 December 2025 the Board of Directors has issued and reissued 1,254,969 warrants, providing the right to subscribe up to 1,254,969 shares, each with a nominal value of DKK 10 (a total nominal value of DKK 12,549,690) at a rate of DKK 216.50 per share of nominal value DKK 10. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants determined by the Board of Directors. 115,012 of the warrants have been reissued under Section 26 of this Appendix 1.

Subscription for shares according to the awarded warrants can be made, wholly or partly, in periods of each 2 weeks (1) first time being after the publication of the Company's annual report for 2028; (2) second time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2029; (3) third time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2029; (4) fourth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2029; (5) fifth time being after the publication of the Company's annual report for 2029; (6) sixth time being after the publication of the Company's quarterly report (Q1) for the first 3 months of 2030; (7) seventh time being after the publication of the Company's quarterly report (Q2) for the first 6 months of 2030; and/or (8) eighth time being after the publication of the Company's quarterly report (Q3) for the first 9 months of 2030. Warrants that are not exercised

electronically in the first subscription period may be exercised in subsequent subscription periods, always provided that any warrants not exercised at the expiry of the last subscription period will lapse without notice and without compensation.

If a warrant holder due to a decision by the Board of Directors not to open or to close a trading window, or due to other extraordinary circumstances is restricted from exercising or trading shares in the Company during the last subscription period, the Board of Directors may grant such a warrant holder a right to exercise warrants during a period of 2 weeks after the first publication by the Company of a quarterly or annual report after the expiry of the last subscription period (an "Extraordinary Window"). The Board of Directors is not obliged to offer a warrant holder an Extraordinary Window and any such decision shall be made in due consideration of the Remuneration Policy. The Board of Directors may decide to expand the subscription period by one or more Extraordinary Windows.

The existing shareholders of the Company do not have any pre-emption rights with regard to the Warrants or shares subscribed for pursuant thereto.

The warrants cannot be assigned or placed as collateral by the warrant holder to third party.

In the event that (i) a majority of the Company's shares is sold, meaning that at least a third of the Company's share capital is transferred to a third party (who may be an existing shareholder of the Company) or (ii) the Company is dissolved, including by merger or demerger, the Company's Board of Directors may decide:

That warrant holders must exercise all or part of the warrants that have been granted and transfer the shares on the same terms as the other transferring shareholders (or waive the right to such Warrants in which case they will lapse); or

That warrant holders will retain the warrants that have been granted on unchanged terms.

If, before the warrants have been exercised in full, a resolution is passed in the Company to increase the share capital, issue warrants, convertible debt instruments or other instruments, allowing subscription for shares at a price not lower than the market value, this will not affect the terms of the warrants. Nor will the terms of the warrants be affected by any resolution to increase the share capital in order to allow employees, consultants or directors of the Company or its subsidiaries to subscribe for shares at a price which is lower than the market value.

If, before the warrants have been exercised in full, a resolution is passed in the Company (i) to increase the share capital, issue warrants, convertible debt instruments or other instruments to any persons other than the employees, consultants or directors of the Company or its subsidiaries, allowing subscription for shares at a price which is lower than the market value, (ii) to reduce the Company's share capital to cover any

loss, (iii) to reduce the Company's share capital to make distributions to the shareholders, or (iv) to carry out payment of dividend, and such change reduces or increases the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants must be adjusted to ensure that the potential gain on the warrants remains unchanged. If, before the warrants have been exercised in full, a resolution is passed to reduce the Company's share capital to make distributions to the shareholders, and such change does not reduce or increase the potential gain on the warrants, the exercise price and/or the number of shares that may be subscribed for by the exercise of warrants will not be adjusted. Warrants to employees of Bavarian Nordic Inc. are, however, subject to additional adjustment provisions.

For the exercise of awarded warrants, the Board of Directors has decided on an increase of the Company's share capital in one or more portions by a total nominal value of up to DKK 12,549,690 by cash payment at a price of DKK 216.50 per share of nominal value DKK 10 and without pre-emption right for the Company's existing shareholders. The number of shares and the subscription price may, however, be higher or lower as a result of any adjustment made in accordance with the terms of the warrants. The details and terms for the issuance of shares have been established by the Board of Directors.

The warrants granted contain a limitation, in that the total value of the shares that can be subscribed for by exercising the warrants, minus the subscription price that must be paid when the shares are subscribed (the "net value"), at the time the warrants are exercised, must not exceed an amount equivalent to DKK 20 million. If the net value exceeds DKK 20 million, the number of warrants that can be exercised must be reduced so that the net value of the warrants does not exceed DKK 20 million.

In each subscription period, the Company may at its discretion decide that the warrant holder shall exercise his/her warrants by full or partial settlement in treasury shares rather than subscribing for new shares. Settlement in treasury shares may be effected by:

- a) The Company delivering one (1) treasury share of nominally DKK 10 for each exercised warrant against the warrant holder's payment of consideration in an amount equivalent to the subscription price; or
- b) The Company delivering a number of treasury shares with an aggregate market value corresponding to the difference between (i) the aggregate market value of the number of shares that would have been subscribed for under the exercised warrants and (ii) the aggregate subscription price of such warrants. If the difference between the aggregate market value of the shares and the aggregate subscription price does not correspond to the market value of a whole number of treasury shares, the number of treasury shares to be delivered by the Company shall be rounded up or down to the nearest whole number. For the purpose of this subsection b), the market value of the shares in the Company shall be determined based on the average market price (closing price) of the shares in the Company as quoted on the Danish Stock Exchange Nasdaq

Copenhagen over the last five (5) business days prior to expiry of the relevant subscription period.

If the Company decides to exercise the right to settlement in treasury shares, the Company must notify the warrant holder hereof before expiry of the subscription period. If the Company decides to settle in treasury shares as described in subsection b) above, the warrant holder shall not pay the subscription price for the shares under the warrants that are being settled in treasury shares and any part of such subscription price already paid by the warrant holder to the Company will be repaid to the warrant holder within 30 days after expiry of the relevant subscription period.

Holders of warrants shall have pre-emption right to subscribe for the shares issued based on the warrants, meaning that the pre-emption rights to subscribe to warrants and new shares for existing shareholders' are deviated from.

The new shares issued based on issued, reused or reissued warrants shall from the date of registration with the Danish Business Authority have the same rights as existing shares according to the Articles of Association. The new shares shall be negotiable instruments, shall be registered in the names of the holders, and shall be entered in the Company's register of shareholders. No restrictions in the transferability of the new shares shall apply and no shareholder shall be obliged to allow for their shares to be redeemed – in whole or in part. The new shares shall be eligible for dividends from the time of subscription.